Evidence map›Paper›PMID 37463063›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

Learning Individual Survival Models from PanCancer Whole Transcriptome Data.

Neeraj Kumar, Daniel Skubleny, Michael Parkes, Ruchika Verma, Sacha Davis, Luke Kumar, Amira Aissiou, Russell Greiner

Open access · hybridAbstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Neeraj KumarAlberta Machine Intelligence Institute, Edmonton, Alberta, Canada.ORCID 0000-0002-3221-3831
Daniel SkublenyDepartment of Surgery, University of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0001-8243-6139
Michael ParkesComputing Science Department, University of Alberta, Edmonton, Alberta, Canada.ORCID 0000-0002-1502-7535
Ruchika VermaAlberta Machine Intelligence Institute, Edmonton, Alberta, Canada.ORCID 0000-0003-4870-128X
Sacha DavisAlberta Machine Intelligence Institute, Edmonton, Alberta, Canada.ORCID 0000-0003-0295-162X
Luke KumarMicrosoft, Vancouver, British Columbia, Canada.ORCID 0000-0002-5129-2598
Amira AissiouAlberta Health Services, Edmonton, Alberta, Canada.ORCID 0000-0002-3061-7744
Russell GreinerAlberta Machine Intelligence Institute, Edmonton, Alberta, Canada.ORCID 0000-0001-8327-934X
University of Alberta · CANorthern Alberta Institute of Technology · CAAlberta Health Services · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePersonalized medicine attempts to predict survival time for each patient, based on their individual tumor molecular profile. We investigate whether our survival learner in combination with a dimension reduction method can produce useful survival estimates for a variety of patients with cancer. EXPERIMENTAL

designThis article provides a method that learns a model for predicting the survival time for individual patients with cancer from the PanCancer Atlas: given the (16,335 dimensional) gene expression profiles from 10,173 patients, each having one of 33 cancers, this method uses unsupervised nonnegative matrix factorization (NMF) to reexpress the gene expression data for each patient in terms of 100 learned NMF factors. It then feeds these 100 factors into the Multi-Task Logistic Regression (MTLR) learner to produce cancer-specific models for each of 20 cancers (with >50 uncensored instances); this produces "individual survival distributions" (ISD), which provide survival probabilities at each future time for each individual patient, which provides a patient's risk score and estimated survival time.

resultsOur NMF-MTLR concordance indices outperformed the VAECox benchmark by 14.9% overall. We achieved optimal survival prediction using pan-cancer NMF in combination with cancer-specific MTLR models. We provide biological interpretation of the NMF model and clinical implications of ISDs for prognosis and therapeutic response prediction.

conclusionsNMF-MTLR provides many benefits over other models: superior model discrimination, superior calibration, meaningful survival time estimates, and accurate probabilistic estimates of survival over time for each individual patient. We advocate for the adoption of these cancer survival models in clinical and research settings.

Indexed as

NeoplasmsTranscriptomeAlgorithmsHumans

Identifiers

PMID37463063
PMCPMC10543961
OpenAlexW4384664196

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.